New Therapeutic Avenues for Treatment of Fibrosis: Can We Learn from Other Diseases?
- 1 December 2014
- journal article
- review article
- Published by S. Karger AG in Digestive Diseases
- Vol. 32 (Suppl. 1) , 39-49
Abstract
Crohn's disease (CD) is characterized by the frequent occurrence of complications, such as fibrotic strictures and subsequently the need for CD-related surgery. Chronic or recurrent inflammation is generally regarded to be a necessary precondition for the initiation of intestinal fibrosis. In this view, fibrosis is a pathologically augmented healing response to inflammation-induced mucosal tissue destruction and injury. At present, there are no approved or effective medical therapies aimed specifically at fibrosis or stricture in IBD. Indirect benefits may occur from anti-inflammatory therapies, although there is no consensus on this. Therapy for fibrosis is complicated by the fact that a wound-healing response is essential in CD and ulcerative colitis. Several pharmaceutical companies are now working on the therapy of fibrosis in other diseases. Strategies interfering with TGF-β expression and activation are promising. Pirfenidone has been studied in several clinical trials. Further therapeutic options are second-generation and wide-spectrum tyrosine kinase inhibitors. These inhibit growth factor receptor signaling, thus reducing fibrosis in animal models and some patients with tumor-associated fibrosis. At present, the development of antifibrotic therapies takes place in other diseases such as lung and liver fibrosis. This is partially due to a lack of experimental models for gut fibrosis and the fact that reliable readouts (MRI, serum markers) in patients are lacking. It will be important to test the above-mentioned newly available treatment strategies in IBD to profit from progress in other fibrotic diseases.Keywords
This publication has 103 references indexed in Scilit:
- Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary FibrosisNew England Journal of Medicine, 2012
- SAMP1/YitFc mouse strain: A spontaneous model of Crohnʼs disease-like ileitisInflammatory Bowel Diseases, 2011
- Development of the Crohnʼs disease digestive damage score, the Lémann scoreInflammatory Bowel Diseases, 2011
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- Magnetization Transfer Helps Detect Intestinal Fibrosis in an Animal Model of Crohn DiseaseRadiology, 2011
- Amelioration of excess collagen IαI, fibrosis, and smooth muscle growth in TNBS-induced colitis in IGF-I(+/−) miceInflammatory Bowel Diseases, 2011
- A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2010
- Identification of Epithelial to Mesenchymal Transition as a Novel Source of Fibroblasts in Intestinal FibrosisJournal of Biological Chemistry, 2010
- Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-AnalysisGastroenterology, 2008
- Monocyte chemoattractant protein-1 (MCP-1) inhibits the intestinal-like differentiation of monocytesClinical and Experimental Immunology, 2006